Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592323 | 0.89 | POLB (0.42) | GRM5RENGAAKDM2BALDH1A1 | |
| SCHEMBL3571520 | 0.84 | KAT6A (0.46) | RENGAARAB9AALDH1A1MEN1 | |
| SCHEMBL3565628 | 0.84 | KAT6A (0.46) | RENGAARAB9AALDH1A1MEN1 | |
| SCHEMBL3885007 | 0.79 | GAA (0.38) | GAARAB9AKDM2BALDH1A1MEN1 | |
| SCHEMBL5318682 | 0.76 | KDM2B (0.49) | GAARAB9AKDM2BALDH1A1MEN1 | |
| SCHEMBL5593533 | 0.76 | REN (0.42) | GRM5RENL3MBTL1 | |
| SCHEMBL5593253 | 0.73 | KDM2B (0.43) | GAARAB9AKDM2BALDH1A1MEN1 | |
| SCHEMBL2847273 | 0.73 | POLB (0.47) | GRM5KDM2BALDH1A1MEN1KMT2A | |
| SCHEMBL2850274 | 0.73 | KAT6A (0.49) | RENALDH1A1MEN1KMT2A | |
| SCHEMBL2850273 | 0.73 | KAT6A (0.49) | RENALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117560-A2 | PIPERIDINE AND MORPHOLINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |